NAFLD stands for Non-Alcoholic Fatty Liver Disease. A new study conducted on the subject matter of this disease suggests that the low-levels of the amino acids in this disease might hold the key to the treatment for the diseases. This chronic liver disease currently does not have therapy or a drug for the cure of it. However, the low-glycine circulated blood in the patients’ body can become a future for the potential medical treatment to generate a glycine-based treatment. The glycine-based treatment to the NAFLD patients can attenuate the hepatic fatty acids and cause the synthesis of the clinical evolution.
A random clinical trial and test conducted by the medical researchers found that the patients who received a genetic test for the lowering of cholesterol and their side effects in the body did not possess worst outcomes in a year of the trial.
Some laboratories across the world offer the Pharmacogenetic testing – which depicts the patients’ ability to the vulnerable side effects of certain medications, by studying their genetic structure. However, the FDA raised concerns on this issue as the people might self-medicate based on the results of pharmacogenetic testing, which an cause harm sooner or later.
The primary aim of the Global Health Organizations is to provide primary healthcare and a strategy for disease elimination on a global scale.
After the eradication of Smallpox in the year 1979, the aim of these health communities has shifted to an expanded realm, setting their sights on the elimination of other deadly diseases like malaria, Tuberculosis and Polio. Although it sounds easy and fancy on paper, the hunt for an exact cure for these diseases follows a complex and comprehensive procedure.
According to the Sustainable Development Goal 3 of the Global Health Community, the measure is taken, targeting the eradication of epidemics like Aids, Malaria and TB, by the end of 2030.
That said, for a group of the neglected diseases, the eradication of them is not far from reach, all thanks to the better diagnosis and medical facilities in the isolated and rural areas.
Neglected Tropical Diseases (NTD)
NTDs are taking over the globe, especially the lives of the people living in the isolated regions of Africa, Asia, and Latin America. This is because the people living in those regions do not have access to clean drinking water or safer disposal of human waste. Some of the traumatizing NTDs in such areas include;
- Buruli Ulcer
- Dengue Fever
- Chagas Disease
- Leprosy or Hansen’s Disease
Measures taken to reach the goals
After extensive research, it was found that one of the best ways to control the spread or the further occurrences of the diseases mentioned above is to control its vectors like black flies and mosquitoes, improving basic sanitation, and imparting hygiene.
On January 20th, 2012, many of the pharmaceutical companies, NGOs, Government organizations and other health stakeholders, signed declarations endorsing the WHO with an NTD eradication roadmap. The roadmap included the absolute annihilation of 10 NTDs.
Every year, the NTDs affect over one billion people and most times, authorities and responsible organizations do not bat an eye because it happens with poverty and the lower sections of the society. Although the 2020 roadmap is stuck in between without reaching the destination, it still managed to ignite the fire to fight this spurring increase in the advocacy and the expertise of the diseases.
After years of studying the possible conditions and applying formulas to diminish the NTDs, one common question arises – Have these effects helped?
- The NTD roadmap targeted a global eradication of the sleeping sickness by the year 2020, but it recorded a historic low of fewer than 1000 cases in 2018.
- The roadmap has successfully eradicated the HAT in Uganda and Ivory Coast.
Although the achievements and targets of the ambitions goal of beating NTDs are not wholly reached, it still has managed to find solutions and trials for medicines and vacancies for most of the NTDs in the rural, isolated and the areas below the poverty line.
Over the years, clinical research on various epidemic and pandemic diseases were conducted with in-person interactions. However, since COVID-19 transmits rapidly through human touch and touches on the surfaces, the scenario has forced for the rapid adjustment in the virtual modes of communication. This means that medical researchers are finally adapted to embrace change in their clinical trials. They have also suggested that, by making these changes permanent, it could also enhance the effectiveness of the research.
Clinical research post-COVID
In response to the spread of the COIVD-19 pandemic, the regulatory changes to accommodate all the clinical trials and research appeared rapidly. For instance, this also included the barriers that prevent patient care units via telemedicine services. In the same way, the FDA also initiated all the alternative methods for the safety of the medical researchers and their assessments. This also included the virtual visit assessments, which paved a way to shift to the rapid virtual modes of interaction between the patients and the health professionals.
- One take away from the virtual model of assessment is the “Teleresearch” methods that place events on the current landmark of clinical trials.
- The introduction of teleconference also reduces the protocol of the meeting and investigation meeting, which could be another way to stop the spread of future viruses during epidemics and pandemics.
The process of obtaining valid information from the patients and the reports from the clinical trials are ethical and also a traditional way of performing clinical trials. This also provides a greater area for improving the methods of teleresearch, which also dramatically improves and enhances patient experience. That said, signing consent papers and signatures on the documents can be intrusive for the patients as well as the families, especially if they suffer from critical illnesses like the COVID-19.
Extending the research capabilities
Most of the outcomes of the clinical researchers, including the ones like the exams, surveys, and telemetry, can be used to conduct the best clinical trials, especially during the COVID-19 pandemic. It can be done telemetrically, whose outcomes are more critical and handy in the identification of their side effects.
The data collected through technologies like artificial intelligence and the wearable monitors allows the participants to collect data and perform safer clinical trials on the accuracy of the information gained during the assessment.
Clinical research and trials are the long-awaited catalysts that help in processing and adapting to technological changes. One of the much-needed catalysts for the change in traditional ways was the COVID-19 pandemic that can prepare people well for the next crisis.
Drinking is a common form of entertainment for young adults and an escape from reality to the older generation. However, it causes more harm than what we have speculated over the years. Some of the studies conducted in the matter of brain health and drinking indicate that binge drinking in adolescence can lead to a reduced percentage of the grey and white matter in the brain, affecting its functioning.
While, the same amount of drinking can reduce the brains’ health in the older generation, also reaching out to the cognitive function of the brain. Even moderate drinking leads to a diminished effect in brain volume.